You have free access to this content

Cancer

Cover image for Cancer

15 May 2005

Volume 103, Issue 10

Pages 1985–2207

  1. Review Article

    1. Top of page
    2. Review Article
    3. Original Articles
    1. You have free access to this content
      The role of clofarabine in hematologic and solid malignancies—Development of a next-generation nucleoside analog (pages 1985–1995)

      Stefan Faderl, Varsha Gandhi, Michael J. Keating, Sima Jeha, William Plunkett and Hagop M. Kantarjian

      Version of Record online: 31 MAR 2005 | DOI: 10.1002/cncr.21005

      • original image
      • original image

      Clofarabine is a next-generation nucleoside analog with activity in adult and pediatric leukemias. The authors report that development continues in lymphoproliferative disorders and solid tumors. New combination regimens to enhance its activity are being designed.

  2. Original Articles

    1. Top of page
    2. Review Article
    3. Original Articles
    1. Disease Site

      Breast Disease
      You have free access to this content
      Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction (pages 1996–2005)

      Joy Melnikow, Debora Paterniti, Rahman Azari, Christina Kuenneth, Stephen Birch, Miriam Kuppermann, James Nuovo, Janet Keyzer and Stuart Henderson

      Version of Record online: 11 APR 2005 | DOI: 10.1002/cncr.20981

      • original image

      Two hundred fifty-five women who potentially were eligible to use tamoxifen for breast cancer risk reduction were interviewed about their preferences and decision-making after an educational session. Less than 20% of women were interested in tamoxifen after education about the potential benefits and harms, despite very high self-perceived breast cancer risk.

    2. You have free access to this content
      The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes (pages 2006–2014)

      Pauline T. Truong, Eric Berthelet, Junella Lee, Hosam A. Kader and Ivo A. Olivotto

      Version of Record online: 5 APR 2005 | DOI: 10.1002/cncr.20969

      • original image
      • original image
      • original image
      • original image

      The presence of > 25% positive lymph nodes was an adverse prognostic factor in patients with breast carcinoma who had T1–T2 tumors and 1–3 positive lymph nodes. This variable may be used to identify patients who are at high risk of postmastectomy locoregional and distant recurrence.

    3. Endocrine Disease
      You have free access to this content
      Prognostic value of CD44 isoform expression in thymic epithelial neoplasms (pages 2015–2022)

      Satoshi Sonobe, Hideaki Miyamoto, Bunsei Nobukawa, Hiroshi Izumi, Toshiro Futagawa, Noboru Ishikawa, Akio Yamazaki, Toshimasa Uekusa, Hiroshi Abe and Koichi Suda

      Version of Record online: 13 APR 2005 | DOI: 10.1002/cncr.21046

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      In the current study, CD44v6 expression demonstrated a significant difference between thymic tumors with regard to the World Health Organization tumor type, invasive potential of the tumor, and risk of recurrence, provided an appropriate level of CD44v6 positivity is selected. Accordingly, CD44v6 appears to be a useful marker that reflects the disease stage of thymic epithelial neoplasms.

    4. Gastrointestinal Tract
      You have free access to this content
      Mucinous carcinomas of the colon and rectum show higher rates of microsatellite instability and lower rates of chromosomal instability : A study matched for T classification and tumor location (pages 2023–2029)

      Yoshihiro Kazama, Toshiaki Watanabe, Takamitsu Kanazawa, Tomohiro Tada, Junichiro Tanaka and Hirokazu Nagawa

      Version of Record online: 5 APR 2005 | DOI: 10.1002/cncr.21022

      • original image
      • original image
      • original image

      Mucinous carcinomas of the colon and rectum show different characteristics according to tumor location and show higher rates of microsatellite instability and lower rates of chromosomal instability than well differentiated adenocarcinomas matched for T classification and tumor location.

    5. Genitourinary Disease
      You have free access to this content
      Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy (pages 2030–2034)

      Kozhaya N. Mallah, Christopher J. DiBlasio, Audrey C. Rhee, Peter T. Scardino and Michael W. Kattan

      Version of Record online: 8 APR 2005 | DOI: 10.1002/cncr.20991

      • original image

      Several studies have suggested an association between body mass index (BMI) and disease progression after radical prostatectomy. The authors examined this association and that between the reciprocal of BMI (INVBMI, 1/BMI) and progression-free probability in men treated with radical retropubic prostatectomy for clinically localized prostate carcinoma.

    6. You have free access to this content
      A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma (pages 2035–2041)

      Jonathan E. Rosenberg, Hans von der Maase, John D. Seigne, Jozef Mardiak, David J. Vaughn, Malcolm Moore, Deepak Sahasrabudhe, Peter A. Palmer, Juan Jose Perez-Ruixo and Eric J. Small

      Version of Record online: 5 APR 2005 | DOI: 10.1002/cncr.21023

      • original image

      In this Phase II study, the farnesyl transferase inhibitor R115777 showed minimal activity against transitional cell carcinoma of the urothelial tract.

    7. You have free access to this content
      Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy (pages 2042–2052)

      Mayank M. Agarwal, Niranjan Khandelwal, Arup K. Mandal, Satyawati V. Rana, Vivek Gupta, Vaddi Chandra Mohan and Gottapu V. M. K. Kishore

      Version of Record online: 13 APR 2005 | DOI: 10.1002/cncr.21047

      • original image
      • original image
      • original image
      • original image
      • original image

      In the current study, osteoporosis was common in the age group of men affected by prostate carcinoma and was accelerated by orchidectomy. Quantitative computed tomography was a sensitive tool for detecting changes in bone mineral density (BMD). Periodic assessment of BMD and the knowledge of factors that modify it (e.g. weight, body mass index, physical activity, addiction to smoking and alcohol, and dietary calcium intake) would help to initiate antiosteoporosis treatment early.

    8. You have free access to this content
      The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma (pages 2053–2059)

      Paul L. Nguyen, Richard Whittington, Sophia Koo, Delray Schultz, Kerri B. Cote, Marian Loffredo, Elizabeth McMahon, Andrew A. Renshaw, John E. Tomaszewski and Anthony V. D'Amico

      Version of Record online: 6 APR 2005 | DOI: 10.1002/cncr.21050

      • original image
      • original image
      • original image
      • original image

      A delay in initiating radiation therapy appears to adversely affect prostate-specific antigen outcome for patients with high-risk, clinically localized, prostate carcinoma. This effect was not seen in low-risk patients.

    9. You have free access to this content
      Symptomatic local recurrence of prostate carcinoma after radiation therapy (pages 2060–2066)

      Dan Leibovici, Andrew K. Lee, Rex M. Cheung, Philippe E. Spiess, Deborah A. Kuban, Charles J. Rosser, Yu Shen, Ying Yang, Ramsey Chichakli and Louis L. Pisters

      Version of Record online: 8 APR 2005 | DOI: 10.1002/cncr.20990

      • original image
      • original image
      • original image
      • original image

      In this study, the authors found that the risk for symptomatic local recurrence of prostate carcinoma after radiation therapy was 3.4%. Clinical predictors of this debilitating event included aggressive histologic subtype, high Gleason score, advanced T classification, and elevated prostate-specific antigen.

    10. You have free access to this content
      Intraoperative, radio-guided sentinel lymph node mapping in laparoscopic lymph node dissection for Stage I testicular carcinoma (pages 2067–2072)

      Makoto Satoh, Akihiro Ito, Yasuhiro Kaiho, Haruo Nakagawa, Seiichi Saito, Mareyuki Endo, Chikara Ohyama and Yoichi Arai

      Version of Record online: 31 MAR 2005 | DOI: 10.1002/cncr.21049

      • original image
      • original image
      • original image
      • original image

      The authors investigated the feasibility and accuracy of radio-guided sentinel lymph node (SLN) mapping for patients with Stage I testicular carcinoma. Almost all SLNs were detected accurately by the procedure.

    11. Head and Neck Disease
      You have free access to this content
      Postoperative complications of salvage total laryngectomy (pages 2073–2081)

      Ian Ganly, Snehal Patel, Jeanette Matsuo, Bhuvanesh Singh, Dennis Kraus, Jay Boyle, Richard Wong, Nancy Lee, David G. Pfister, Ashok Shaha and Jatin Shah

      Version of Record online: 6 APR 2005 | DOI: 10.1002/cncr.20974

      • original image

      Salvage laryngectomy is more frequently associated with postoperative complications after chemoradiotherapy (CTRT) compared with primary total laryngectomy. Multivariate analysis showed that primary CTRT was an independent predictor of local wound complications and pharyngocutaneous fistula.

    12. Hematologic Malignancies
      You have free access to this content
      Disease biology rather than age is the most important determinant of survival of patients ≥ 60 years with acute myeloid leukemia treated with uniform intensive therapy (pages 2082–2090)

      Vikas Gupta, Kathy Chun, Qi-Long Yi, Mark Minden, Andre Schuh, Richard Wells and Joseph Brandwein

      Version of Record online: 13 APR 2005 | DOI: 10.1002/cncr.21006

      • original image
      • original image

      One hundred seventeen patients ≥ 60 years were treated with induction and modified high-dose cytosine arabinoside containing postremissin therapy. The major adverse predictors for survival were cytogenetics and high leukocyte count. Age was not a risk factor for complete disease remission or overall survival in this group.

    13. You have free access to this content
      Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma : The M. D. Anderson Cancer Center experience (pages 2091–2098)

      Maricer P. Escalón, Nina S. Liu, Ying Yang, Mark Hess, Pamela L. Walker, Terry L. Smith and Nam H. Dang

      Version of Record online: 6 APR 2005 | DOI: 10.1002/cncr.20999

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Patients with T-cell lymphoma treated with intensive therapies did not fare better than those treated with the regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone therapy. Pretreatment parameters that may be independent prognostic factors for survival in patients with T-cell lymphoma, excluding patients with T-cell anaplastic large cell lymphoma, included ECOG performance status ≥ 2, beta-2-microglobulin level > 2 mg/L, lactate dehydrogenase levels higher than normal, bulky disease (≥ 7 cm in diameter), and a high international prognostic index and tumor score.

    14. You have free access to this content
      Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia—Comparison with historic experience (pages 2099–2108)

      Hagop Kantarjian, Moshe Talpaz, Susan O'Brien, Francis Giles, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, Jianqin Shan, Mary Beth Rios, Richard Champlin, Marcos de Lima and Jorge Cortes

      Version of Record online: 13 APR 2005 | DOI: 10.1002/cncr.21032

      • original image
      • original image
      • original image
      • original image

      The authors compared their long-term experience using imatinib in the treatment of patients with accelerated-phase chronic myelogenous leukemia (CML) with the experience in a group of historic control patients. The results suggest that imatinib improved survival compared with other therapies in patients with accelerated-phase CML.

    15. You have free access to this content
      Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma (pages 2109–2117)

      Antonino Musolino, Maria Antonietta Perrone, Maria Michiara, Daniela Delnevo, Vittorio Franciosi, Beatrice Di Blasio, Guido Ceci, Roberta Camisa, Andrea Ardizzoni and Giorgio Cocconi

      Version of Record online: 31 MAR 2005 | DOI: 10.1002/cncr.21024

      • original image
      • original image
      • original image

      Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin is a novel salvage regimen for patients with aggressive non-Hodgkin lymphoma. It has clinically significant activity with a favorable toxicity profile in primary refractory disease and in patients treated for second or subsequent disease recurrences.

    16. Lung Disease
      You have free access to this content
      Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma (pages 2118–2127)

      Kenneth E. Rosenzweig, Jana L. Fox, Ellen Yorke, Howard Amols, Andrew Jackson, Valerie Rusch, Mark G. Kris, Clif C. Ling and Steven A. Leibel

      Version of Record online: 13 APR 2005 | DOI: 10.1002/cncr.21007

      • original image
      • original image
      • original image
      • original image
      • original image

      In a Phase I dose-escalation trial that was conducted at the Memorial Sloan-Kettering Cancer Center, the maximum tolerated dose of thoracic radiation with three-dimensional, conformal radiotherapy for nonsmall cell lung carcinoma, with a normal tissue complication probability constraint of 25%, was 84 grays (Gy). There was a suggestion of improved survival in patients who received > 80 Gy.

    17. You have free access to this content
      Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein : A Phase II clinical trial (pages 2128–2131)

      Lee M. Krug, John P. Crapanzano, Christopher G. Azzoli, Vincent A. Miller, Naiyer Rizvi, Jorge Gomez, Mark G. Kris, Barbara Pizzo, Leslie Tyson, Megan Dunne and Robert T. Heelan

      Version of Record online: 5 APR 2005 | DOI: 10.1002/cncr.21000

      • original image

      The current Phase II study evaluated the efficacy of imatinib in patients with recurrent small cell lung carcinoma expressing c-kit protein. Imatinib demonstrated no activity in this group of patients.

    18. Neuro-Oncology
      You have free access to this content
      Expression and structure of interleukin 4 receptors in primary meningeal tumors (pages 2132–2142)

      Sachin Puri, Bharat H. Joshi, Chitra Sarkar, Ashok Kumar Mahapatra, Ejaz Hussain and Subrata Sinha

      Version of Record online: 13 APR 2005 | DOI: 10.1002/cncr.21008

      • original image
      • original image
      • original image

      The authors studied the expression and structure of interleukin 4 (IL-4) receptor subunits, e.g., IL-4 receptor α chain (IL-4Rα), IL-2γc, and IL-12Rα1, in primary human meningiomas by using reverse transcriptase-polymerase chain reaction (PCR) analysis and confirmed their results with real-time PCR and immunofluorescence analyses. The IL-4Rα and IL-13Rα1 subunits were expressed in meningiomas at a higher level compared with control normal brain tissues. There was no overexpression of IL-γ2c. This indicated that type II IL-4Rs were overexpressed in these tumors. Thus, IL-4R may serve as a target for immunotherapy or immunotoxin therapy for patients with recurrent meningiomas or who are not amenable to surgery.

    19. You have free access to this content
      Perineural spread of cutaneous malignancy to the brain : A review of the literature and five patients treated with stereotactic radiotherapy (pages 2143–2153)

      B. Zach Fowler, Ian R. Crocker and Peter A. S. Johnstone

      Version of Record online: 6 APR 2005 | DOI: 10.1002/cncr.21004

      • original image
      • original image
      • original image

      Previous reports generally have recommended that patients with intracranial perineural spread receive palliative external-beam radiotherapy. Some of these patients may have prolonged survival, or even may be cured. Judicious use of stereotactic radiotherapy should be considered in their management.

    20. Discipline

      Diagnostic Imaging
      You have free access to this content
      Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening (pages 2154–2162)

      Cynthia O. Townsend, Matthew M. Clark, James R. Jett, Christi A. Patten, Darrell R. Schroeder, Liza M. Nirelli, Stephen J. Swensen and Richard D. Hurt

      Version of Record online: 11 APR 2005 | DOI: 10.1002/cncr.21045

      • original image
      • original image
      • original image
      • original image

      In a longitudinal study with 1520 current and former smokers, smokers receiving multiple abnormal chest computed tomography (CT) scan screenings for lung carcinoma were more likely to abstain from smoking at the 3-year follow-up. Multiple chest CT scan screenings may represent teachable moments and opportunities to enhance motivation for smoking abstinence.

    21. Epidemiology
      You have free access to this content
      High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colonic adenocarcinomas (pages 2163–2170)

      Dominik Alexander, Nirag Jhala, Chakrapani Chatla, Jon Steinhauer, Ellen Funkhouser, Christopher S. Coffey, William E. Grizzle and Upender Manne

      Version of Record online: 6 APR 2005 | DOI: 10.1002/cncr.21021

      • original image

      African Americans with high-grade tumors were 3 times more likely to die of colon carcinoma within 5 years postsurgery, compared with Caucasians with high-grade tumors. The racial disparity in colon carcinoma mortality observed in previous studies may, in part, be contributable to high-grade tumor differentiation among African-American patients.

    22. Pediatric Oncology
      You have free access to this content
      Survivors of childhood cancer and their guardians : Current health behaviors and receptivity to Health Promotion Programs (pages 2171–2180)

      Wendy Demark-Wahnefried, Cary Werner, Elizabeth C. Clipp, Ann Bebe Guill, Melanie Bonner, Lee W. Jones and Philip M. Rosoff

      Version of Record online: 5 APR 2005 | DOI: 10.1002/cncr.21009

      • original image
      • original image

      Data from a mailed survey of 209 survivors of childhood leukemia, lymphoma, or central nervous system carcinomas (age range, 11–33 years) suggested that approximately 42% were overweight or obese, 10% smoked, and most did not meet national guidelines for fruit and vegetable consumption (79%), calcium intake (68%), and exercise (52%). Despite suboptimal lifestyle practices, this population reported receptivity to mailed interventions specifically aimed at getting in shape and eating healthy.

    23. Radiation Oncology
      You have free access to this content
      Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma (pages 2181–2188)

      Shi-Xiong Liang, Xiao-Dong Zhu, Hai-Jie Lu, Chao-Yang Pan, Fu-Xiang Li, Qi-Fang Huang, An-Yu Wang, Long Chen, Xiao-Long Fu and Guo-Liang Jiang

      Version of Record online: 5 APR 2005 | DOI: 10.1002/cncr.21012

      • original image
      • original image
      • original image
      • original image
      • original image

      Hypofractionated three-dimensional conformal radiotherapy is effective in carefully selected primary liver carcinoma with better overall survival for patients with smaller gross tumor volume or Child–Pugh A cirrhosis. Gastrointestinal complications and radiation-induced liver disease were the most severe complications.

    24. Symptom Control and Palliative Care
      You have free access to this content
      Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care—Correlations with food intake, metabolism, exercise capacity, and hormones (pages 2189–2198)

      Marita Fouladiun, Ulla Körner, Ingvar Bosaeus, Peter Daneryd, Anders Hyltander and Kent G. Lundholm

      Version of Record online: 8 APR 2005 | DOI: 10.1002/cncr.21013

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Body composition metabolism and physical functioning were investigated in relation to circulating hormone levels in unselected cancer patients who were receiving palliative care. The results may prove important in the planning of efficient palliative treatment for patients with cancer.

    25. Translational Research
      You have free access to this content
      Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells (pages 2199–2207)

      Ryungsa Kim, Kazuaki Tanabe, Manabu Emi, Yoko Uchida and Tetsuya Toge

      Version of Record online: 13 APR 2005 | DOI: 10.1002/cncr.21029

      • original image
      • original image
      • original image
      • original image

      The modulation of tamoxifen sensitivity by antisense Bcl-2 was superior to the modulation achieved by trastuzumab in breast carcinoma cell lines that expressed HER-2 and Bcl-2. Antisense Bcl-2 appeared to be superior to trastuzumab with respect to regulation of the signal-transduction pathways involved in breast carcinoma cells.

SEARCH

SEARCH BY CITATION